AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01210430
Drug: Ascorbic Acid (Vitamin C)
RxNorm normalized name: Ascorbic acid (vitamin C), plain
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive 60mg/kg of Ascorbic Acid over 20 minutes followed by a maintenance infusion of 20mg/kg.
Trial: NCT01210430
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 60mg/kg of normal saline over 20 minutes followed by a maintenance infusion of 20mg/kg of normal saline.
Trial: NCT00811902
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, oral administration
Trial: NCT01209065
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus -1 infection by ViiV Healthcare. This drug is experimental and has not been approved by the Food and Drug Administration (FDA).
Trial: NCT01817894
Drug: Eflornithine cream 11.5 w/w %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split face intervention with application of Eflornithine cream 11.5 w/w % versus no treatment for six months
Trial: NCT02779699
Drug: AL2846
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL2846 p.o. qd
Trial: NCT03083561
Drug: LY3337641
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT03083561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT01870362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01746420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium acetate buffer (0 mg rhPDGF-BB)
Trial: NCT01817582
Drug: Soothe® Lubricant Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006280
Drug: Tobramycin for Inhalation
RxNorm normalized name: tobramycin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01486901
Drug: isophane human insulin
RxNorm normalized name: insulin isophane, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
Trial: NCT02296190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
Trial: NCT00085202
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02280239
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one-time dose of acetaminophen 650mg given via the enteral route (via the gut)
Trial: NCT02280239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one-time dose of placebo (identical capsule) given via the enteral route (via the gut)
Trial: NCT03866083
Drug: Extracorporeal Cytokine hemadsorption therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoperfusion will be carried out for one session within 12 hours for all randomized patient using the adsorption columns for Jianfan Biotechnology Co., Zhuhai, China). The hemoperfusion apparatus will be connected in front of the hemodialyzer in series.
Trial: NCT01690091
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.
Trial: NCT01862263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of vildagliptin
Trial: NCT01399047
Drug: Liquid Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
Trial: NCT03131713
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000mg
Trial: NCT02515565
Drug: cephalosporin with or without erythromycin
RxNorm normalized name: erythromycin Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second- or third-generation cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin, given parenterally; parenteral therapy should continue until the patient has been afebrile for more than 24 hours and oxygen saturation exceeds 95 percent.
Trial: NCT01283334
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For phase I, dose escalation will be 2.5 mg, 5 mg, 7.5 mg or 10 mg given orally on a daily basis.
Trial: NCT00373672
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical in appearance to active comparator
Trial: NCT03233529
Drug: Placebo ointment (vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment (vehicle) BID for 15 days (double blind)
Trial: NCT00476268
Drug: Beclometasone dipropionate 250 µg/unit dose pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations bid
Trial: NCT04437368
Drug: GT005; Low Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 of the study will test two doses of GT005: Low Dose and High Dose.
Trial: NCT04437368
Drug: GT005; High Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 of the study will test two doses of GT005: Low Dose and High Dose.
Trial: NCT04437368
Drug: GT005; Low Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 2 of the study will test one dose: Low Dose.
Trial: NCT03430479
Drug: Cohort A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation + Nivolumab + hormone therapy
Trial: NCT04242433
Drug: Direct Acting Antivirals
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects with viremic chronic hepatitis C will be given DAAs based on the MMPHCRF Treatment algorithm. Patients will be assessed for cirrhosis, prior treatment exposure, high risk groups like dialysis patients, HIV-HCV coinfection, etc. Accordingly treatment will be provided at any of the 25 peripheral centres or at the apex nodal treatment centre (PGIMER) of the MMPHCRF.~Baseline and post treatment RAS samples will be collected with consent.
Trial: NCT04317430
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose tablets
Trial: NCT00177853
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will start celecoxib (200mg PO BID) beginning 3-5 days prior to chemoradiation at home and receive the drug until 30 days following the completion of chemoradiation.
Trial: NCT00601172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match IV casopitant
Trial: NCT02383368
Drug: ASP4132
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04158674
Drug: Cernevit
RxNorm normalized name: Cernevit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mixture of 12 vitamins The dilution of the treatment is done in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min
Trial: NCT01154569
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg single dose
Trial: NCT02422966
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02219581
Drug: Standard multimodal pain management regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standard multimodal postoperative pain management regimen typically used for total knee arthroplasty consists of the following:~Preoperative:~* Decadron: 10 or 20mg IV x 1 2 doses, 8 hours apart (if randomized to study group)~Intraoperative:~* Ropivacaine: Given intraoperatively. Capsule, subcutaneous tissue/skin. Administered in standard fashion. (300mg)~* Toradol: 30mg q 6hr for 6 total doses. 1st dose given intraoperatively at incision. The dose is 15 mg for older patients or if creatinine clearance (CrCl) is low.~Postoperative~* Tylenol: 1000mg po q 8hr (scheduled)~* Oxycodone: 5mg or 10mg q 3-4hr prn pain, If intolerant to Oxycodone: second agent line is Hydrocodone or Oral Dilaudid~* IV Morphine (or Dilaudid): 1 or 2 mg q 2hr prn breakthrough pain~* Morphine patient-controlled analgesia (PCA): only for failure of the above~* Morphine Sulfate (MS) Contin: Use as backup prn pain
Trial: NCT02219581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the placebo arm will receive two doses of saline intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
Trial: NCT02162719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received oral placebo matched to ipatasertib, daily on Days 1-21 of each 28-day cycle.
Trial: NCT01115920
Drug: MTP-131 (Bendavia™)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 4 hour intravenous infusion
Trial: NCT00697086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02936544
Drug: BAY987521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code:Z09-054)
Trial: NCT00920985
Drug: Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 7 cycles and placebo patches matching the conditions of the treatment of Arm 1
Trial: NCT02000700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One matching placebo tablet orally administered at baseline phase.
Trial: NCT01762839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
Trial: NCT00614523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
Trial: NCT01060202
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Patients receiving bortezomib injection intravenously (into a vein) 1.3 mg/m2 twice a week for 21 days will be observed.
Trial: NCT01037595
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 3 time orally for 8 weeks
Trial: NCT02382640
Drug: Maalox Advance Regular Strength liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent
Trial: NCT02339350
Drug: high dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HD-MTX IV 5,000 mg/m2 I.V. over 4hr on day 0, 14, 28, 42 of SER interim maintenance schedule
Trial: NCT00869284
Drug: CEEP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclophosphamide 1200 mg/m² intravenously on day 1 (d1), epirubicin 100 mg/m² intravenously on d1, vindesine 3 mg/m² intravenously on d1 and prednisone 80 mg/m² orally or intravenously on d1-5, with two weeks intervals
Trial: NCT04481230
Drug: 99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg (D0)
Trial: NCT04481230
Drug: 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg (D0)
Trial: NCT04481230
Drug: 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg (D0)
Trial: NCT04638881
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo. Bolus and infusion administered similarly under general anesthesia.
Trial: NCT01989689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02232308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
Trial: NCT03794219
Drug: oral naproxen
RxNorm normalized name: naproxen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg/day oral naproxen is administered for 10 days.
Trial: NCT00712881
Drug: Liposomal doxorubicin hydrochloride
RxNorm normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
Trial: NCT00712881
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered per dose and schedule specified in the arm description.
Trial: NCT00712881
Drug: Free doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Free doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
Trial: NCT02261948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
Trial: NCT00526669
Drug: Lapatinib and Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral lapatinib (1250mg) administered as a monotherapy run-in followed by its combination with capecitabine
Trial: NCT02089230
Drug: MEK 162
RxNorm normalized name: Mitogen-activated protein kinase (MEK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.~Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I.
Trial: NCT03014895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT02149758
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00091247
Drug: tetracycline hydrochloride
RxNorm normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04454398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluent
Trial: NCT01382472
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg per operative in PPCI, the 40 daily during hospital stay
Trial: NCT01382472
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No statin acutely. Simvastatin 20 mg from day 2.
Trial: NCT01452997
Drug: NSAI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 5% gel
Trial: NCT01452997
Drug: Steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid intervention with 0.05% w/w clobetasone butyrate.
Trial: NCT05139667
Drug: Corticosteroid Topical
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical tacrolimus and corticosteroids
Trial: NCT04392128
Drug: Azithromycin 250 MG Oral Capsule
RxNorm normalized name: azithromycin 250 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin is amacrolide antibiotic.
Trial: NCT04392128
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Hydroxychloroquine Sulfate 200 MG \[Plaquenil\].
Trial: NCT04392128
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Azithromycin capsules.
Trial: NCT01980407
Drug: S-1, leucovorin, oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (20mg), capsule, 40-60mg, bid, p.o., day1-14； Leucovorin (15 mg), tablet, 30mg,Bid, p.o., day1-14; Oxaliplatin (50 mg), injection 85mg/m2, day1.
Trial: NCT01337674
Drug: MK-4618
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
Trial: NCT01337674
Drug: Placebo for MK-4618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
Trial: NCT00733174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02115659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain, etc.
Trial: NCT02044627
Drug: [14C-ETC-1002]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00222365
Drug: Bryonia alba, 5 CH
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00222365
Drug: Hypericum perforatum, 5 CH
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00222365
Drug: Ruta graveolens, 3 DH
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00737204
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo pills matched to the active armodafinil and according to the same dosing strategy
Trial: NCT01712009
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
Trial: NCT00503022
Drug: ACZ885
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03350334
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration
Trial: NCT02240108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
Trial: NCT03041779
Drug: Paracetamol 500Mg Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01991275
Drug: The intravenous patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intravenous injection of morphine using the patient-controlled analgesia machine
Trial: NCT03530631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered placebo
Trial: NCT00827515
Drug: PH797804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fasted state
Trial: NCT00827515
Drug: PH797804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fed state
Trial: NCT03308591
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platin based chemotherapy
Trial: NCT01677884
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Every 3 weeks: 2000 mg/m²/d in 2 times/d from D1 to D4
Trial: NCT03257852
Drug: ASP5094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenously administration
Trial: NCT03257852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenously administration
Trial: NCT04447352
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1 q2w: 200 mg/m² IV over 30 minutes
Trial: NCT03479918
Drug: R-DA-EPOCH-21
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-DA-EPOCH-21 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
Trial: NCT03479918
Drug: R-BL-M-04
RxNorm normalized name: M/R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-BL-M-04 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
Trial: NCT03479918
Drug: R-DA-EPOCH-21 + auto-SCT
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-DA-EPOCH-21 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
Trial: NCT03479918
Drug: R-BL-M-04 + auto-SCT
RxNorm normalized name: M/R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-BL-M-04 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.